{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:27Z","timestamp":1778843367506,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848043001"],"award-info":[{"award-number":["848043001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["17 - 992"],"award-info":[{"award-number":["17 - 992"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102974","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T03:18:43Z","timestamp":1619234323000},"page":"102974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Natalizumab discontinuation in a Dutch real-world cohort"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-9996","authenticated-orcid":false,"given":"E.M.E.","family":"Coerver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.J.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-8966","authenticated-orcid":false,"given":"Z.Y.G.","family":"van Lierop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102974_bib0001","article-title":"Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population","volume":"6","author":"Conway","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.102974_bib0002","article-title":"Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort","author":"Bigaut","year":"2020","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.msard.2021.102974_bib0003","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102974_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1352458514541507","article-title":"Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy","volume":"21","author":"Vennegoor","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102974_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000904","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","volume":"8","author":"Toorop","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102974_bib0006","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102974_bib0007","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.msard.2021.102974_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ane.12250","article-title":"What to expect after natalizumab cessation in a real-life setting","volume":"130","author":"Salhofer-Polanyi","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2021.102974_bib0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2021.102974_bib0010","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.102974_bib0011","article-title":"Mild disease course of carry-over progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","author":"Toorop","year":"2020","journal-title":"MSVirtual"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:27Z","timestamp":1778840907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":11,"alternative-id":["S2211034821002418"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102974","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natalizumab discontinuation in a Dutch real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102974"}}